Recursion reported Q3 2024 revenue of $26.1M, up from $10.5M YoY, driven by its Roche-Genentech partnership including a $30M fee for a neuroscience phenomap option. The company ended Q3 with $427.6M in cash. Net loss was $95.8M compared to $93.0M in Q3 2023, with R&D expenses increasing to $74.6M from $70.0M YoY.Multiple clinical milestones were achieved, including positive Phase 2 CCM trial data, first patient dosed in Phase 2 C. difficile trial, and IND clearance for Phase 1/2 trial in biomarker-enriched solid tumors. The company expanded its collaboration with Google Cloud to enhance its drug discovery platform capabilities.The proposed business combination with Exscientia continues to progress, with a special shareholder meeting scheduled for November 12, 2024 and expected scheme arrangement date of November 20, 2024. The merger aims to create an industry-leading technology-enabled small molecule discovery platform.

Recursion reported Q3 2024 revenue of $26.1M, up from $10.5M YoY, driven by its Roche-Genentech partnership including a $30M fee for a neuroscience phenomap option. The company ended Q3 with $427.6M in cash. Net loss was $95.8M compared to $93.0M in Q3 2023, with R&D expenses increasing to $74.6M from $70.0M YoY.Multiple clinical milestones were achieved, including positive Phase 2 CCM trial data, first patient dosed in Phase 2 C. difficile trial, and IND clearance for Phase 1/2 trial in biomarker-enriched solid tumors. The company expanded its collaboration with Google Cloud to enhance its drug discovery platform capabilities.The proposed business combination with Exscientia continues to progress, with a special shareholder meeting scheduled for November 12, 2024 and expected scheme arrangement date of November 20, 2024. The merger aims to create an industry-leading technology-enabled small molecule discovery platform.